Cancer Research
Pharma company initiates Tarvacin phase I therapy clinical trial
Published in AIDS Weekly, July 11th, 2005
The clinical trial is open to patients with any advanced refractory solid tumor malignancy. The initial clinical centers open for patient enrollment are the Scottsdale and Tucson sites of the Arizona Cancer Center.
The clinical trial is designed to enroll up to 28 patients with advanced solid tumors that no longer respond to standard cancer treatments. The objectives of this open-label dose escalation study are to (i) determine the safety and tolerability of Tarvacin administered intravenously to patients with advanced cancer; (ii)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-07-11)
More Articles from AIDS Weekly
- HIV/AIDS & Measles
Maternal HIV infection may reduce levels of measles antibodies in newborns - HIV/AIDS Diagnostics
Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor comparable to manual method - HIV/AIDS Immunology
HIV-specific IgA can neutralize HIV replication inside cells - HIV/AIDS Prognosis
Females w/ 104-105 baseline VLs have lower risk of HIV progress than men - HIV/AIDS Prognosis
Immunologic factors predict long-term nonprogression in HIV-infected children - Advocacy
Provider of HIV/AIDS medical care lauds U.S. Rep. Henry Waxman's stand on CAFTA - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
